e-learning
resources
ERS Research Seminars
2007
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Inflammation and vascular dysfunction
B. Staels (Lille, France)
Source:
Research Seminar 2007 - Metabolic Aspects of the Obstructive Sleep Apnea Syndrome (OSAS)
Number:
9
Disease area:
Sleep and breathing disorders
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Staels (Lille, France). Inflammation and vascular dysfunction. Research Seminar 2007 - Metabolic Aspects of the Obstructive Sleep Apnea Syndrome (OSAS)
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Adherence predictors to positive airway pressure (PAP) treatment in patients with obstructive sleep apnea (OSA)
The search for realistic evidence on the outcomes of obstructive sleep apnoea
PERIPHERAL ARTERIAL TONOMETRY AND INTIMA MEDIA THICKNESS IN OBSTRUCTIVE SLEEP APNEA.
Related content which might interest you:
Impaired endothelial vasoreactivity and markers of systemic inflammation in overlap syndrome
Source: Annual Congress 2013 –Sleep disordered breathing in special situations I
Year: 2013
Endothelial CFTR dysfunction and its involvement in the pathogenesis of pulmonary arterial hypertension
Source: Eur Respir J, 58 (2) 2101645; 10.1183/13993003.01645-2021
Year: 2021
Vascular dysfunction and systemic inflammation in patients with COPD
Source: Annual Congress 2011 - COPD: human studies
Year: 2011
Systemic inflammation and vascular dysfunction in patients with OSA
Source: Annual Congress 2011 - Obstructive sleep apnoea: clinical aspects I
Year: 2011
Pulmonary hypertension: the science behind the disease spectrum
Source: Eur Respir Rev 2012; 21: 19-26
Year: 2012
Systemic inflammation and endothelial dysfunction in patient with COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 143s
Year: 2007
Endothelial dysfunction of patients with pulmonary hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 25s
Year: 2002
Endothelial dysfunction as systemic effects of COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 652s
Year: 2006
Primary pulmonary hypertension and endothelial dysfunction
Source: Eur Respir J 2003; 22: Suppl. 45, 583s
Year: 2003
Endothelial and platelet dysfunction in pulmonary hypertension due to sarcoidosis
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Correction of endothelial dysfunction in patients with pulmonary diseases
Source: Annual Congress 2008 - Sarcoidosis and other interstitial lung diseases
Year: 2008
Pulmonary vascular cell mitochondrial dysfunction in response to hepcidin
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
Pulmonary arterial hypertension in scleroderma – manifestation of systemic endothelial dysfunction
Source: Eur Respir J 2006; 28: Suppl. 50, 548s
Year: 2006
Role of endothelin-1 in endothelial dysfunction in cystic fibrosis
Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know?
Year: 2007
Smooth muscle microparticles as novel biomarkers of vascular remodelling and inflammation in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Inflammatory mediators contribute to pulmonary arterial cell dysfunction in a pulmonary arterial hypertension patient with
BMPR2
mutation
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
The evaluation of airways mucosa vascular endothelial dysfunction
Source: Eur Respir J 2004; 24: Suppl. 48, 560s
Year: 2004
Endothelial dysfunction and arterial rigidity in patients with bronchial asthma out of an exacerbation
Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation
Year: 2013
Cardiac dysfunction
Source: Research Seminar 2021 – Unravelling severe exacerbations of COPD – CICERO an ERS CRC
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept